Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Fox
Kevin R
KR
Division of Hematology/Oncology, University of Pennsylvania School of Medicine, 16 Penn Tower, Philadelphia, PA 19104, USA. kevin.fox@uphs.upenn.edu
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004164:Diphosphonates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000401:mortality; D009570:Nitriles / Q000627:therapeutic use; D017697:Premenopause; D011379:Prognosis; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077211:Zoledronic Acid